Background:Anterior cruciate ligament injury and anterior cruciate ligament reconstruction (ACLR) are risk factors for symptomatic posttraumatic osteoarthritis (PTOA). After ACLR, individuals demonstrate altered joint tissue metabolism indicative of increased inflammation and cartilage breakdown. Serum biomarker changes have been associated with tibiofemoral cartilage composition indicative of worse knee joint health but not with PTOA-related symptoms.Purpose/Hypothesis:The purpose of this study was to determine associations between changes in serum biomarker profiles from the preoperative sample collection to 6 months after ACLR and clinically relevant knee PTOA symptoms at 12 months after ACLR. It was hypothesized that increases in biomarkers of inflammation, cartilage metabolism, and cartilage degradation would be associated with clinically relevant PTOA symptoms after ACLR.Study Design:Case-control study; Level of evidence, 3.Methods:Individuals undergoing primary ACLR were included (N = 30). Serum samples collected preoperatively and 6 months after ACLR were processed to measure markers indicative of changes in inflammation (ie, monocyte chemoattract protein 1 [MCP-1]) and cartilage breakdown (ie, cartilage oligomeric matrix protein [COMP], matrix metalloproteinase 3, ratio of type II collagen breakdown to type II collagen synthesis). Knee injury and Osteoarthritis Outcome Score surveys were completed at 12 months after ACLR and used to identify participants with and without clinically relevant PTOA-related symptoms. K-means cluster analyses were used to determine serum biomarker profiles. One-way analyses of variance and logistic regressions were used to assess differences in Knee injury and Osteoarthritis Outcome Score subscale scores and clinically relevant PTOA-related symptoms between biomarker profiles.Results:Two profiles were identified and characterized based on decreases (profile 1: 67% female; age, 21.4 ± 5.1 years; body mass index, 24.4 ± 2.4) and increases (profile 2: 33% female; age, 21.3 ± 3.2 years; body mass index, 23.4 ± 2.6) in sMCP-1 and sCOMP preoperatively to 6 months after ACLR. Participants with profile 2 did not demonstrate differences in knee pain, symptoms, activities of daily living, sports function, or quality of life at 12 months after ACLR compared to those with profile 1 ( P = .56-.81; η2 = 0.002-0.012). No statistically significant associations were noted between biomarker profiles and clinically relevant PTOA-related symptoms (odds ratio, 1.30; 95% CI, 0.23-6.33).Conclusion:Serum biomarker changes in MCP-1 and sCOMP within the first 6 months after ACLR were not associated with clinically relevant PTOA-related symptoms.

中文翻译：

---

ACLR 术后 12 个月时关节组织炎症和软骨代谢的血清生化生物标志物谱与创伤后骨关节炎相关症状的关联


背景：前交叉韧带损伤和前交叉韧带重建（ACLR）是症状性创伤后骨关节炎（PTOA）的危险因素。 ACLR 后，个体表现出关节组织代谢的改变，表明炎症和软骨破坏增加。血清生物标志物变化与表示膝关节健康状况较差的胫股软骨成分相关，但与 PTOA 相关症状无关。 目的/假设：本研究的目的是确定从术前样本收集到 6 年间血清生物标志物谱变化之间的关联。 ACLR 后数月以及 ACLR 后 12 个月时临床相关膝关节 PTOA 症状。据推测，炎症、软骨代谢和软骨退化等生物标志物的增加与 ACLR 后临床相关的 PTOA 症状相关。证据级别，3。方法：纳入接受初次 ACLR 的个体（N = 30）。对术前和 ACLR 后 6 个月收集的血清样本进行处理，以测量指示炎症变化的标志物（即单核细胞趋化蛋白 1 [MCP-1]）和软骨破坏（即软骨寡聚基质蛋白 [COMP]、基质金属蛋白酶 3、 II 型胶原蛋白分解与 II 型胶原蛋白合成的比率）。膝关节损伤和骨关节炎结果评分调查在 ACLR 后 12 个月完成，用于识别有或没有临床相关 PTOA 相关症状的参与者。 K-均值聚类分析用于确定血清生物标志物谱。 使用方差和逻辑回归的单向分析来评估生物标志物谱之间膝关节损伤和骨关节炎结果评分子量表评分以及临床相关 PTOA 相关症状的差异。 结果：根据下降情况识别和表征了两个谱图（谱图 1：67） % 女性；年龄，21.4 ± 5.1 岁；体重指数，24.4 ± 2.4），术前 sMCP-1 和 sCOMP 有所增加（概况 2：33% 女性；年龄，21.3 ± 3.2 岁；体重指数，23.4 ± 2.6）至 ACLR 后 6 个月。与概况 1 的参与者相比，概况 2 的参与者在 ACLR 术后 12 个月时，在膝关节疼痛、症状、日常生活活动、运动功能或生活质量方面没有表现出差异（P = .56-.81；η2 = 0.002- 0.012）。生物标志物谱与临床相关 PTOA 相关症状之间没有统计学上的显着关联（比值比，1.30；95% CI，0.23-6.33）。结论：ACLR 后前 6 个月内 MCP-1 和 sCOMP 的血清生物标志物变化与临床相关的 PTOA 相关症状无关。